Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): A randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet Oncology.
Times cited: 145
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update.
European Journal of Cancer.
Times cited: 271
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial.
Journal of Clinical Oncology.
Times cited: 1739